Health TrialsbyHealthPanel

Irisin Hormone as a Novel Diagnostic Marker for Detection and Progression of Diabetic Nephrophathy Patients

ConditionDiabetic Nephropathies
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age30-75
SponsorSohag University

About this trial

Study the relation between irisin level and progression of diabetic nephropathy and its early detection.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

Non-diabetic kidney diseases.

Acute illness, infection, obesity, hypertension, type 1 DM.

Malignancy, other endocrine disorders, corticosteroid drugs, pregnancy, lactation.

Trial population

Type 2 diabetic patients between 30-75 years old

Trial design

Design model

Case-only

Time perspective

Cross-sectional

Treatments tested in this trial

  • HBa1c

    Diagnostic test

    Rapid method for detection of diabetes

  • glucose

    Diagnostic test

    accurate method for diabetes

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

1

Measure number of Participants With Diabetic nephropathy Adverse healthy people as Assessed by irisin hormone ).

Participants With Diabetic nephropathy Adverse healthy people as Assessed by irisin hormone ).

Time frame
Two years

Secondary outcomes

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Sohag University

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: